Gilead Breaks Ground on $32B US Manufacturing Hub Creating 3,000 Jobs

Gilead Sciences has commenced construction on a new Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City, California headquarters, as part of its $32 billion investment plan in U.S. domestic manufacturing through 2030. The five-story, 180,000-square-foot facility will incorporate advanced digital infrastructure, autonomous robotics, and real-time monitoring to support biologics development, a key component of Gilead's growth strategy. This project is one of three currently under development at the Foster City campus, alongside a research building and a biologics manufacturing facility. Gilead projects these investments will create over 3,000 direct and indirect jobs and generate more than $43 billion in economic value nationwide, aligning with President Trump's push to increase domestic pharmaceutical production. CEO Daniel O’Day emphasized the facility as a cornerstone for delivering next-generation therapies and enhancing U.S. biopharma leadership. The company aims for the center to become one of the most AI-enabled in the biopharma industry, focusing on advancing treatments across virology, oncology, and inflammation.